Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Daniel A. Pryma Clear advanced filters

  • Gitto, Pantel et al. evaluate a PARP-targeted PET imaging ligand, [18 F]FlourThanatrace, as a biomarker of response to PARP inhibitors in patients with breast cancer. There is [18 F]FlourThanatrace uptake in the tumor before treatment, and a decline in uptake after PARP inhibitor therapy initiation, correlating with patient progression free survival.

    • Sarah B. Gitto
    • Austin R. Pantel
    • Elizabeth S. McDonald
    ResearchOpen Access
    Communications Medicine
    Volume: 5, P: 1-8

  • In this study, involving melanoma patients and a mouse model for melanoma, an optimal anti-tumour response was induced by using a combination of radiation with anti-CTLA4 and anti-PD-L1 antibody therapies, each attacking the tumour from a different angle.

    • Christina Twyman-Saint Victor
    • Andrew J. Rech
    • Andy J. Minn
    Research
    Nature
    Volume: 520, P: 373-377